Rigel Pharmaceuticals | RIGL - Sales Revenues


Rigel Pharmaceuticals reported $55.31M in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Agenus USD 34.2M 3.97M Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 73.74M 190.29M Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Celldex Therapeutics USD 15K 106K Mar/2026
Daiichi Sankyo JPY 587B 28.89B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Ligand Pharmaceuticals USD 51.72M 7.94M Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Veracyte USD 139.07M 1.53M Mar/2026